# Bioequivalency Study of CM082 Tablet in Healthy Volunteers

> **NCT04328506** · PHASE1 · COMPLETED · sponsor: **AnewPharma** · enrollment: 96 (actual)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** CM082 tablet (test product)
- **DRUG:** CM082 tablet (reference product)

## Key facts

- **NCT ID:** NCT04328506
- **Lead sponsor:** AnewPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2020-07-27
- **Final completion:** 2020-07-27
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04328506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04328506, "Bioequivalency Study of CM082 Tablet in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04328506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*